Augur Signals: News Feed

Report Archive – March 2024

Augur Signals: News Feed
Biotechnology , Healthcare , Alert

Insider Buying at Design Therapeutics: What It Means for the Stock's Future

  • Acquired: Non-Derivative
Insider Buying at Design Therapeutics: What It Means for the Stock's Future
On March 22, 2024, John P. Schmid, a director of Design Therapeutics, Inc., acquired 26,965 shares of common stock valued at approximately $102,466.99. The stock closed at $3.80, with a high volume of 940,400 shares, indicating strong investor interest. Technical indicators show bullish momentum, though the company has a negative P/E ratio. A target price of $4.10 to $4.20 is predicted within 5-10 days, with potential to reach $4.50 in four weeks. Despite positive signals, investors should consider the company's negative earnings.
Drug Manufacturers - Specialty & Generic , Healthcare , Alert

Insider Trading Alert: A Strategic Move by Maraoui Claude at Journey Medical Corporation

  • Acquired: Non-Derivative
Insider Trading Alert: A Strategic Move by Maraoui Claude at Journey Medical Corporation
On March 22, 2024, Maraoui Claude of Journey Medical Corporation purchased 10,000 shares at $3.30 each, totaling $33,000. The healthcare sector shows volatility, with the stock's recent price lower than the 16-week average of $4.95, indicating potential undervaluation. Despite a negative P/E ratio of -66.17, the P/S ratio of 1.44 suggests near fair value. The stock could rise to $3.50 short-term, amid mixed valuation signals and insider confidence.
Medical Devices , Healthcare , Alert

Insider Activity Alert: Aharon Gil Buys Delcath Systems, Inc. Shares

  • Acquired: Non-Derivative
Insider Activity Alert: Aharon Gil Buys Delcath Systems, Inc. Shares
On March 19, 2024, Aharon Gil of Delcath Systems, Inc. purchased 26,882 shares for about $115,054.97, increasing his holdings to 1,069,710 shares. Operating in the Healthcare sector, the company showed a closing price of $4.28 with a signal price of $4.58. Despite negative P/E ratios, the stock's high P/B and P/S ratios indicate overvaluation. Short-term predictions suggest a rise to $4.70, with potential stabilization around $4.40 due to technical indicators.
Biotechnology , Healthcare , Alert

Insider Trading Alert: Levin Jeremy M Buys Ovid Therapeutics Inc. Stock

  • Acquired: Non-Derivative
Insider Trading Alert: Levin Jeremy M Buys Ovid Therapeutics Inc. Stock
On , Levin Jeremy M, a director of Ovid Therapeutics Inc., purchased 18,248 shares of Common Stock at $2.73 each, totaling approximately $49,817.04. This increased his holdings to 3,616,715 shares. Despite mixed performance in the biotechnology sector, Levin Jeremy M has a history of positive returns. Ovid Therapeutics Inc. shows a P/E ratio of -1.66, a P/B ratio of 0.87, and a high P/S ratio of 104.96. Technical indicators suggest bearish momentum, with predictions of slight price stabilization.
Oil & Gas E&P , Energy , Alert

Insider Trading Alert: Brandenberg Luke C Buys Granite Ridge Resources, Inc. Stock

  • Acquired: Non-Derivative
Insider Trading Alert: Brandenberg Luke C Buys Granite Ridge Resources, Inc. Stock
On , Brandenberg Luke C, an officer at Granite Ridge Resources, Inc., purchased 5,084.0979 shares on the New York Stock Exchange for approximately $31,250. The transaction suggests confidence in the company's future, supported by a positive ROI history of 11.76%. The stock, priced at $6.1478, shows modest undervaluation with a P/E ratio of 9.17 and a P/B ratio of 1.28. A short-term bullish sentiment is expected with a price increase of 2-3%, targeting $6.27 to $6.33, extending to 3-5% in the coming weeks.
Biotechnology , Healthcare , Alert

Insider Buying at Rezolute, Inc. Sparks Interest: What Could Be the Next Price Move?

  • Acquired: Non-Derivative
Insider Buying at Rezolute, Inc. Sparks Interest: What Could Be the Next Price Move?
On March 15, 2024, Evans Daron, an officer at Rezolute, Inc., purchased 20,000 Common Shares valued at approximately $35,600. This transaction is part of a trend, marking his 13th purchase in a year. Known for a strong ROI of 21.44% on transactions older than four weeks, his actions indicate confidence in the company's growth. The stock, priced at $1.85 on March 19, 2024, shows potential for upward movement, with technical indicators suggesting bullish momentum. Predictions estimate short-term price increases to $2.00 to $2.10, reflecting positive market sentiment.
Medical Devices , Healthcare , Alert

Insider Trading Alert: Analyzing the Recent Purchase by Albert DaCosta in Paragon 28, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Analyzing the Recent Purchase by Albert DaCosta in Paragon 28, Inc.
On March 15, 2024, Albert DaCosta, a director and ten percent owner of Paragon 28, Inc., purchased 28,000 shares of Common Stock at $9.12 per share, totaling approximately $255,360. This increased his shares to 5,339,110. Despite mixed market sentiments in the healthcare sector, his strategic acquisitions often yield positive returns. Paragon 28, Inc. shows a negative P/E Ratio of -21.08 but a high P/B Ratio of 6.01. The insider's purchase suggests a potential short-term bullish movement, predicting a price increase to $9.25 to $9.46 in the immediate term.
Biotechnology , Healthcare , Alert

Insider Buying at ALX Oncology Holdings Inc.: What Does It Mean for the Stock?

  • Acquired: Non-Derivative
Insider Buying at ALX Oncology Holdings Inc.: What Does It Mean for the Stock?
On March 14, 2024, Jason Lettmann, a director and major shareholder of ALX Oncology Holdings Inc., purchased 4,400 shares valued at approximately $49,060. This insider transaction on NASDAQ suggests confidence in the company's future within the Biotechnology industry. The stock closed at $11.15 with a signal price of $11.0225, indicating potential volatility. Technical indicators like RSI and MACD suggest the stock is oversold, hinting at a rebound. Predictions indicate a short-term rise to $11.50-$11.75 with stabilization at $11.75-$12.25 in the following weeks.
Furnishings, Fixtures & Appliances , Consumer Cyclical , Alert

Insider Buying Alert: What Does It Mean for Traeger, Inc.?

  • Acquired: Non-Derivative
Insider Buying Alert: What Does It Mean for Traeger, Inc.?
Jeremy Andrus, an insider at Traeger, Inc., purchased 184,589 shares valued at approximately $441,167.73, increasing his total to 6,998,464 shares. This transaction aligns with a broader market trend, as the Nasdaq Composite shows resilience. Although Traeger, Inc. has mixed valuation metrics, the insider's history of transactions yielding a 20.69% ROI suggests potential for positive price movement. Predictions indicate a short-term price increase to $2.50 - $2.55, reflecting insider confidence in the company's prospects.
Medical Instruments & Supplies , Healthcare , Alert

Insider Trading Alert: Aimee S Weisner's Strategic Move in STAAR Surgical Company

  • Acquired: Non-Derivative
Insider Trading Alert: Aimee S Weisner's Strategic Move in STAAR Surgical Company
Aimee S Weisner, a director at STAAR Surgical Company, purchased 1,755.5221 shares of Common Stock, increasing her holdings to 10,864 shares with a market value of $66,762.50. Her tenure since February 10, 2011 includes 60 transactions, reflecting her market acumen with an ROI of 875.66%. The stock closed at $38.03 on the transaction day, amidst a volume of 907,000 shares. Valuation metrics show a P/B ratio of 2.87, P/E ratio of 30.59, and P/S ratio of 3.61. The stock is predicted to rise to $39.50 to $40.00 in the short term, …

Back

Pages total: 3

Calendar